Article Text

Download PDFPDF

4CPS-226 Effectiveness of carboxymaltose iron in preoperative anaemia treatment
  1. M Alonso Moreno1,
  2. H Rodriguez Ramallo1,
  3. JL Perez Blanco1,
  4. MT Perez Maroto2,
  5. ME Mingot Castellano3,
  6. R Rubio Romero4
  1. 1Hospital Universitario Virgen Del Rocío, Pharmacy, Sevilla, Spain
  2. 2Hospital Universitario Guadalajara, Pharmacy, Sevilla, Spain
  3. 3Hospital Universitario Virgen Del Rocío, Haematology, Sevilla, Spain
  4. 4Hospital Universitario Virgen Del Rocío, Anaesthesia, Sevilla, Spain


Background and importance The administration of carboxymaltose intravenous iron (CII) contributes significantly to the correction of perioperative anaemia and reduction of red blood cell transfusion (RBCT). RCBT is associated with an increased risk of prolonged hospitalisation and mortality, so is recommended to use alternatives to RBCT to improve clinical outcomes and patient safety.

Aim and objectives To evaluate the effectiveness of CII for surgical patients in a third level hospital and to describe the transfusional requirements of patients after the surgical procedure.

Material and methods This was an observational, retrospective, single centre study including surgical patients who received CII between January 2017 and December 2018. Variables collected from the electronic clinical charts were: sex, age, CII dose, baseline and perioperative haemoglobin (HB), and time between CII administration and the surgical procedure. Exclusion criteria were: patients not undergoing surgery, administration CII after surgery and no preoperative or baseline HB data.

The main variable used to evaluate effectiveness was the percentage of patients with an increase in HB in the preoperative stage compared with baseline HB >1 g/dL, and the difference and number of transfusions after the surgical procedure. Data were expressed as mean±SD, and the analysis test used was the χ2 test.

Results 70 patients were included, 48 women (68.6%), with a mean age of 58.3±15.0 years. The mean CII dose was 1274.3±352.5 mg. Mean baseline and preoperative HB were 9.8±1.2 and 11.0±1.4 g/dL, respectively. The time between administration of CII and surgery was 37.7±41.2 days. 78.6% (n=55) had an increase in HB in the preoperative stage compared with baseline HB, and 50.0% (n=35) of patients had an increase in HB >1 g/dL. 35.7% (n=25) of patients were transfused: patients who reached HB in the perioperative stage compared with baseline HB >1 g/dL were transfused less frequently than patients who did not reach this difference (72.0% vs 28.0%) (p=0.006)

Conclusion and relevance CII was clinically effective due to an increase in HB in most patients. In addition, CII administration reduced RCBT for the included patients. However, a comparative study with a cohort of surgical patients without CII administration is needed.

Conflict of interest No conflict of interest

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.